Journal
CURRENT OPINION IN PEDIATRICS
Volume 18, Issue 2, Pages 112-118Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.mop.0000193292.09894.b7
Keywords
adjunctive therapy; bacterial meningitis in children; neuronal damage
Categories
Funding
- NINDS NIH HHS [2P50 NS035902-06] Funding Source: Medline
Ask authors/readers for more resources
Purpose of review The mortality of bacterial meningitis can reach 30%, and up to 50% of survivors suffer from persisting neurological deficits as a consequence of the disease. The incidence of neurological sequelae of bacterial meningitis has not improved over the last decade. Adjunctive therapeutic options are limited, and ongoing research into the pathophysiology of brain damage in bacterial meningitis aims at providing the scientific basis for future development of more efficient adjunctive options. Recent findings In a population with good access to health care, dexamethasone given before or at the time of initiation of antibiotic therapy acts beneficially in pediatric pneumococcal meningitis, but not in meningococcal meningitis. In experimental animal models, brain-derived neurotrophic factor protected against brain injury and improved hearing while melatonin, which has antioxidant properties among other effects, reduced neuronal death. Transgene technology can be used to provide new insights into the pathophysiology of the disease and to identify potential therapeutic targets. Summary Although dexamethasone improves outcome of bacterial meningitis under defined circumstances, the morbidity of bacterial meningitis still remains unacceptably high. Experimental models may help to identify new therapeutic strategies to further improve the neurological outcome in young children suffering from bacterial meningitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available